The atherogenicity of triglyceride-rich lipoprotein has been revealed. This study was performed to explore the clinical importance of triglyceride-rich lipoprotein by measuring its cholesterol content and comparing it with other lipoprotein fractions. Blood samples were obtained from 103 patients whose fasting plasma triglyceride concentration exceeded 300 mg/dl. The cholesterol monitor using the technique of high-performance liquid chromatography was used for the measurement of their plasma cholesterol concentrations and the determination of cholesterol distribution among lipoprotein fractions. This monitor showed 4 peaks: large-triglyceride-rich lipoprotein, small-triglyceride-rich lipoprotein, low-density lipoprotein, and high-density lipoprotein. Total cholesterol increased with increasing triglyceride. The increment of total cholesterol was nearly equal to that of small-triglyceride-rich lipoprotein cholesterol. Small-triglyceride-rich lipoprotein cholesterol exceeded low-density lipoprotein cholesterol where plasma triglyceride concentration was over 500 mg/dl. In conclusion, triglyceride-rich lipoprotein may be clinically important for hypertriglyceridemic patients as a source of cholesteryl ester in arteriosclerotic plaques, and increased triglyceride-rich lipoprotein cholesterol may be used as a basis for hypertriglyceridemia atherogenicity. Our study suggests that hypertriglyceridemia should be treated to prevent arteriosclerotic disease.
Key words:
Triglyceride - Hypercholesterolemia - Hypertriglyceridemia - Triglyceride-Rich Lipoprotein - Arteriosclerosis - Apolipoprotein
References
-
1
Bradley W A, Brown M L, Ramprasad M P, Li R, Song R, Gianturco S H.
Antipeptide antibodies reveal interrelationships of MBP 200 and MBP 235: unique apoB-specific receptors for triglyceride-rich lipoproteins on human monocyte-macrophages.
J Lipid Res.
1999;
40
744-752
-
2
Gianturco S H, Ramprasad M P, Song R, Li R, Brown M L, Bradley W A.
Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor.
Atherioscler Thromb Vasc Biol.
1998;
18
968-976
-
3
Matthew L, Brown M L, Ramprasad M P, Umeda P K, Tanaka A, Kobayashi Y, Watanabe T, Shimoyamada H, Kuo W L, Li R, Song R, Bradley W A, Gianturco S H.
A macrophage receptor for apolipoprotein B48: Cloning, expression, and atherosclerosis.
Proc Natl Acad Sci USA.
2000;
97
7488-7493
-
4
Anderson K M, Castelli W P, Levy D.
Cholesterol and mortality: 30 years of follow-up from the Framingham study.
JAMA.
1987;
257
2176-2180
-
5
Scandinavian Simvastatin Survival Study Group.
Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet.
1994;
344
1383-1389
-
6
Shepherd J, Cobbe S M, Ford I, Isles C G, Lorimer A R, Macfarlane P W, McKillop J H, Packard C J, for the West of Scotland Coronary Prevention Study Group.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med.
1995;
333
1301-1307
-
7
Manninen V, Tenkanen L, Koskinen P, Huttunen J K, Manttari M, Heinonen O P, Frick M H.
Joint effects of serum triglyceride and LDL cholesterol concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study.
Circulation.
1992;
85
37-45
-
8
Sniderman A D, Wolfson C, Teng B, Franklin F A, Bachorik P S, Kwiterovich P O Jr.
Association of hyperapobeta lipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis.
Ann Intern Med.
1982;
97
833-839
-
9
Hulley S B, Rosenman R H, Bawol R D, Brand R J.
Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease.
N Engl J Med.
1980;
302
1383-1389
-
10
Bradley W A, Booyse F M, Gianturco S H.
Fibrinolytic and thrombotic factors in atherosclerosis and IHD: the influence of triglyceride rich lipoproteins (TGRLP).
Atherosclerosis.
1994;
108 (Suppl.)
S31-S39
-
11
Austin M A.
Plasma triglyceride and coronary heart disease.
Arterioscler Thromb.
1990;
11
2-14
-
12
Hokanson J E, and Austin M A.
Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.
J Cardiovasc Risk.
1996;
3
213-219
-
13
Hodis H N, Mack W J.
Triglyceride rich lipoproteins and the progression of coronary artery disease.
Curr Opin Lipidol.
1995;
6
209-214
-
14
Falk E.
Why do plaques rupture?.
Circulation.
1992;
86 (Suppl. III)
30-40
-
15
Mizuno K, Arai T, Satomura K, Shibuya T, Arakawa K, Okamoto Y, Miyamoto A, Kurita A, Kikuchi M, Nakamura H, Utsumi A, Takeuchi K.
New percutaneous transluminal coronary angioscopy.
J Am Coll Cardiol.
1989;
13
353
-
16
deFeyter P J, Ozaki Y, Baptista J, Escaned J, Mario C D, de Jaegere P PT, Serruys P W, Roelandt J RTC.
Ischemia-related lesion characteristics in patients with stable or unstable angina. A study with intracoronary angioscopy and ultrasound.
Circulation.
1995;
92
1408-1413
-
17
Ross R.
The pathogenesis of atherosclerosis. A perspective for the 1990s.
Nature.
1993;
362
801-809
-
18 Okazaki M, Sasamoto K, Muramatsu T, Hosaki S. Analysis of plasma lipoproteins by gel permeation chromatography. Handbook of lipoprotein testing. In: Rifai N, Warnick GR, Dominiczak MH (eds). Washington, DC:; AACC press, 1997: 531-548
-
19
Allain C C, Poon L S, Chan C S, Richmond W, Fu P C.
Enzymatic determination of total resum cholesterol.
Clin Chem.
1974;
20
470-475
-
20 Wahlfield A W. Triglyceride determination after enzymatic hydrolysis. In: Bergmeyer HU (ed). Methods of enzymatic analysis. New York:; Academic, 1974: 1831-1835
-
21
Kitahara M, Shinomiya M, Shirai K, Saito Y, Yoshida S.
Frequency and role of apo E phenotype in familial hypercholesterolemia and non-familial hyperlipidemia in the Japanese.
Atherosclerosis.
1990;
82
197-204
-
22
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Report of the expert committee on the diagnosis and classification of diabetes mellitus.
Diabetes Care.
1998;
21 (Suppl. 1)
S5-S19
-
23
Campos E, Nakajima K, Tanaka A, Havel R J.
Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100.
J Lipid Res.
1992;
33
369-380
-
24
Milne R W, Weech P K, Blanchette L, Davignon J, Alaupovic P, Marcel Y L.
Isolation and characterization of apolipoprotein B-48 and B-100 very low density lipoproteins from type III hyperlipoproteinemic subjects.
J Clin Invest.
1984;
73
816-823
-
25
Minnich A, Nordestgaard B G, Zilversmit D B.
A novel explanation for the reduced LDL cholesterol in severe hypertriglyceridemia.
J Lipid Res.
1989;
30
347-355
-
26
Havel R J, Gordon R S Jr.
Idiopathic hyperlipidemia: metabolic studies in an affected family.
J Clin Invest.
1960;
39
1777-1790
Akira Tanaka, M.D.
Third Department of Internal Medicine
Tokyo Medical and Dental University
1-5-45, Yushima, Bunkyo-ku
Tokyo 113-8519
Japan
Telefon: + 81 (3) 5803-5228
Fax: + 81 (3) 5803-5228
eMail: tanaka.med3@tmd.ac.jp
